In this respect, many partial PDE4D inhibitors, namely, BPN14770 [30,34,35], MK-0952 [36], GEBR-32a [32], and chlorbipram [33], have been developed and tested in the clinical trials for the treatment of Alzheimer’s disease. The gene discussed is PDE4D; the disease is Alzheimer disease.